{"disease":{"id":"smallpox","name":"smallpox"},"drugs":{"marketed":[{"drug_id":"tecovirimat-monohydrate","indication_name":"Treatment of Human Smallpox Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TECOVIRIMAT MONOHYDRATE","company_name":"","drug_phase":"marketed","molecular_target":"variola (smallpox) virus","drug_class":"Orthopoxvirus VP37 Envelope Wrapping Protein Inhibitor [EPC]","quality_score":49,"revenue":null,"mechanism":"Tecovirimat is an antiviral drug that targets the variola (smallpox) virus."},{"drug_id":"brincidofovir","indication_name":"human smallpox disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tembexa","generic_name":"BRINCIDOFOVIR","company_name":"Emergent Biodefense","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Tembexa works by inhibiting the replication of viruses."},{"drug_id":"brincidofovir","indication_name":"diseases other than human smallpox disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tembexa","generic_name":"BRINCIDOFOVIR","company_name":"Emergent Biodefense","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":57,"revenue":null,"mechanism":"Tembexa works by inhibiting the replication of viruses."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03699124","title":"Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1129,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT04971109","title":"Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":467,"lead_sponsor_name":"SIGA Technologies","has_results":true},{"nct_id":"NCT02474589","title":"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":449,"lead_sponsor_name":"SIGA Technologies","has_results":true},{"nct_id":"NCT05995275","title":"A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":351,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05846243","title":"Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":334,"lead_sponsor_name":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","has_results":false},{"nct_id":"NCT00437021","title":"MVA Post-Event: Administration Timing and Boost Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04957485","title":"Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"SIGA Technologies","has_results":false},{"nct_id":"NCT00879762","title":"High Dose IMVAMUNE® in Vaccinia-Naive Individuals","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT05976100","title":"Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","has_results":false},{"nct_id":"NCT02038881","title":"Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT07377175","title":"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"China National Biotec Group Company Limited","has_results":false},{"nct_id":"NCT00325975","title":"Immune Responses to Smallpox Vaccination","phase":"","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05762523","title":"Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","has_results":false},{"nct_id":"NCT00646152","title":"Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04485039","title":"Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"SIGA Technologies","has_results":true},{"nct_id":"NCT05935917","title":"Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Emergent BioSolutions","has_results":false},{"nct_id":"NCT04392739","title":"Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"SIGA Technologies","has_results":true},{"nct_id":"NCT01158157","title":"VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Emergent BioSolutions","has_results":true},{"nct_id":"NCT03972111","title":"A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"SIGA Technologies","has_results":false},{"nct_id":"NCT02080767","title":"Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"U.S. Army Medical Research and Development Command","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}